The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cellectar Biosciences Inc shares valued at $8,400 were purchased by Longcor Jarrod on Jan 10 ’25. At $0.28 per share, Longcor Jarrod acquired 30,000 shares. The insider’s holdings grew to 83,141 shares worth approximately $30762.17 following the completion of this transaction.
Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. Earlier on September 13, 2019, ROTH Capital initiated its rating. Their recommendation was “a Buy” for CLRB stock.
Analyzing CLRB Stock Performance
On last trading session,, Cellectar Biosciences Inc [NASDAQ: CLRB] rose 4.01% to $0.37. During the last five days, there has been a drop of approximately -14.36%. Over the course of the year, Cellectar Biosciences Inc shares have jumped approximately 22.24%. Shares of the company reached a 52-week high of $0.6865 on 06/04/25 and a 52-week low of $0.2298 on 01/15/25.
Support And Resistance Levels for Cellectar Biosciences Inc (CLRB)
According to the 24-hour chart, there is a support level at 0.3403, which, if violated, would cause prices to drop to 0.3152. In the upper region, resistance lies at 0.3953. The next price resistance is at 0.4252. RSI (Relative Strength Index) is 54.75 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Cellectar Biosciences Inc (CLRB)?
In terms of Cellectar Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 3328.57% from the previous closing price of $0.35. Analysts anticipate Cellectar Biosciences Inc stock to reach 12 by 2025, with the lowest price target being 12. In spite of this, 1 analysts ranked Cellectar Biosciences Inc stock as Buy at the end of 2025. On December 21, 2016, Ladenburg Thalmann assigned a price target of “a Buy” to the stock and initiated coverage with a $2.70.
